Akroswiss
Developer of intranasal drug-device combination products focused on central nervous system indications. The company develops a midazolam-based intranasal spray delivered via a single-use bi-dose nasal device with a stated 360° delivery functionality. It is pursuing clinical studies and compilation of documentation for European Medicines Agency (EMA) marketing authorization.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Midazolam‑based intranasal spray delivered via bi‑dose nasal device
A midazolam formulation intended for intranasal administration using a single‑use bi‑dose nasal device with 360° delivery functionality. Two intended use cases are premedication for conscious sedation (e.g., to address anxiety or claustrophobia during diagnostic procedures) and rescue treatment for epileptic seizures.
midazolam product portfolio
An intranasal formulation for minimally invasive drug administration featuring a unique 360° design, currently pursuing European marketing authorization for epileptic seizures and conscious sedation.
Midazolam‑based intranasal spray delivered via bi‑dose nasal device
A midazolam formulation intended for intranasal administration using a single‑use bi‑dose nasal device with 360° delivery functionality. Two intended use cases are premedication for conscious sedation (e.g., to address anxiety or claustrophobia during diagnostic procedures) and rescue treatment for epileptic seizures.
midazolam product portfolio
An intranasal formulation for minimally invasive drug administration featuring a unique 360° design, currently pursuing European marketing authorization for epileptic seizures and conscious sedation.
Services
End‑to‑end development activities encompassing formulation, device design, clinical study execution, and regulatory dossier compilation for intranasal therapies.
End‑to‑end development activities encompassing formulation, device design, clinical study execution, and regulatory dossier compilation for intranasal therapies.
Expertise Areas
- Intranasal drug‑device combination development
- Formulation development for nasal delivery
- Device engineering for nasal sprays
- Clinical trial design and execution
Key Technologies
- Intranasal spray delivery systems
- Bi‑dose nasal device engineering
- Drug formulation for nasal administration
- Device performance validation
News & Updates
Akroswiss takes a step forward in the interest of patients closing a multi‑million CHF funding round
Press release describing a seed funding round to support development of a patented midazolam‑based nasal spray and plans to fund R&D, clinical studies, and regulatory activities toward EMA authorization.
Raised several million Swiss francs in a strategic seed funding round to support product development and regulatory activities.
Akroswiss takes a step forward in the interest of patients closing a multi‑million CHF funding round
Press release describing a seed funding round to support development of a patented midazolam‑based nasal spray and plans to fund R&D, clinical studies, and regulatory activities toward EMA authorization.
Raised several million Swiss francs in a strategic seed funding round to support product development and regulatory activities.